Therapeutic Targets

Q: Can Alpha DaRT fit with existing cancer treatments?

Alpha DaRT is designed with a philosophy of Simplicity in Innovation, meaning, that it is designed to fit into the techniques and workflows that clinicians already use. Whether through endoscopic, bronchoscopic, surgical, or image-guided approaches, the delivery systems are built to feel familiar to physicians. This makes it possible for Alpha DaRT to be considered alongside current standards of care, either as a stand-alone local option or in combination with systemic therapies, without requiring entirely new procedures or complex retraining.

From Technology to Therapy: Treating Cancer at the Core

Single Alpha DaRT® Technology, with Broad Therapeutic Reach

Alpha Tau aims to translate the inside‑out power of Alpha DaRT® into care for patients with both superficial and internal organ solid tumors. In all these cases, our goal is the same: target the tumor directly, preserve healthy tissue, and provide oncology teams with tools that integrate seamlessly into existing practice.

Beyond the Primary Tumor Immune Activation Potential

The potential of Alpha DaRT to marry localized tumor destruction with systemic immune protection could mark a paradigm shift in how we treat solid tumors. Alpha DaRT is poised to enable local therapy to do double duty: not only to kill the targeted tumor, but also to spark an immune response that helps hunt down cancer elsewhere. This is the essence of what is known as “the abscopal effect”, where treating one tumor can lead to regression or growth delay of tumors in other parts of the body via immune mechanisms. By reliably inducing this effect, especially when combined with a checkpoint inhibitor, Alpha DaRT could change the treatment paradigm for patients with metastatic or unresectable cancers. It offers the prospect of a one-two punch: direct tumor eradication at the site of disease and a personalized cancer vaccine effect that trains the immune system to seek and destroy cancer cells body-wide – all with minimal side effects or healthy tissue damage and maximal biological efficiency.

Treatment planning and post procedural verification

Our Treatment Planning Software is designed to support precise and consistent Alpha DaRT treatment by enabling clinicians to create an individualized plan which is customized for each patient before the procedure and which is also used to evaluate tumor coverage afterward. Using imaging-based planning, Alpha DaRT sources are placed directly into the tumor a few millimeters apart. Multiple applicators may be used as needed to help ensure coverage of the entire tumor volume.

Strategic Partnerships Across Specialties

Alpha Tau collaborates with a diverse network of medical specialists to bring Alpha DaRT to patients across a variety of tumor types. Our partners include radiation oncologists, who oversee dosimetry and source placement; endoscopists, who perform procedures for internal tumors such as those in the pancreas; surgeons, who treat superficial lesions including head and neck, or skin cancers; and neurosurgeons who treat brain tumors. Medical oncologists evaluate combination strategies with systemic agents. As Alpha Tau continues to expand its clinical trial program to new therapeutic areas, we aim to grow our partnerships to include an even broader range of medical specialties, leveraging multidisciplinary expertise for optimal patient outcomes.

Simplicity in Innovation

Our philosophy of “Simplicity in Innovation” means we specifically engineer the Alpha DaRT to fit already well-established cancer treatment workflows rather than creating new, unfamiliar techniques for the treating physician. Whether it’s EUS for pancreatic cancer, bronchoscopic navigation for lung tumors, or advanced image-guided navigation systems for precise placement in the brain tumor, Alpha DaRT delivery is designed to be seamless and intuitive for oncology teams.

Frequently Asked Question about Therapeutic Targets

For which kinds of cancers can Alpha DaRT be used?

Alpha DaRT is presently available in clinical trials only. Alpha DaRT is currently being studied as a local therapy for a range of solid tumors, in both superficial cancers such as skin and head & neck lesions, as well as in deep-seated cancers in internal organs such as the pancreas, brain, lung, and prostate.

How is Alpha DaRT delivered to tumors inside the body?

Alpha DaRT is administered via customized delivery systems which are based upon the specific tumor location, and which are integrated with existing standard of care workflows. For example, pancreatic tumors may be reached with endoscopic ultrasound (EUS), lung tumors through bronchoscopy, and prostate tumors via ultrasound-guided transperineal placement.

Can Alpha DaRT fit with existing cancer treatments?

Alpha DaRT is designed with a philosophy of Simplicity in Innovation, meaning, that it is designed to fit into the techniques and workflows that clinicians already use. Whether through endoscopic, bronchoscopic, surgical, or image-guided approaches, the delivery systems are built to feel familiar to physicians. This makes it possible for Alpha DaRT to be considered alongside current standards of care, either as a stand-alone local option or in combination with systemic therapies, without requiring entirely new procedures or complex retraining.

Is Alpha DaRT available in clinical trials in the United States?

Alpha DaRT is currently being evaluated in clinical trials in the United States for multiple cancer types. Availability depends on the specific cancer indication and study location.

For more information about Alpha DaRT clinical trials in specific tumor types, please visit the individual therapeutic area pages or visit www.clinicaltrials.gov.